A decade of letrozole: FACE

Por O’Shaughnessy, Joyce
Publicado em 2007

A decade of letrozole: FACE

Por O’Shaughnessy, Joyce
Publicado no Breast Cancer Res Treat (2008)

PARP as a novel therapeutic target in cancer

Por Annunziata, Christina M., O’Shaughnessy, Joyce
Publicado em 2010

The hedgehog pathway in triple‐negative breast cancer

Por Habib, Joyce G., O'Shaughnessy, Joyce A.
Publicado no Cancer Med (2016)

Dendritic Cells, Inflammation and Breast Cancer

Por Palucka, Karolina, Coussens, Lisa M., O’Shaughnessy, Joyce
Publicado em 2013

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis

Por O’Shaughnessy, Joyce, Gradishar, William J., Bhar, Paul, Iglesias, Jose
Publicado em 2013

Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer

Por O'Shaughnessy, Joyce A., Kaufmann, Manfred, Siedentopf, Friederike, Dalivoust, Philippe, Debled, Marc, Robert, Nicholas J., Harbeck, Nadia
Publicado em 2012

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studie...

Por O’Shaughnessy, Joyce, McIntyre, Kristi, Schwartzberg, Lee, Wilks, Sharon, Puhalla, Shannon, Berrak, Erhan, Song, James, Vahdat, Linda
Publicado no Springerplus (2015)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurr...

Por Puhalla, Shannon, Wilks, Sharon, Brufsky, Adam M, O’Shaughnessy, Joyce, Schwartzberg, Lee S, Berrak, Erhan, Song, James, Vahdat, Linda
Publicado no Breast Cancer (Dove Med Press) (2016)

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Por McIntyre, Kristi, O’Shaughnessy, Joyce, Schwartzberg, Lee, Glück, Stefan, Berrak, Erhan, Song, James X., Cox, David, Vahdat, Linda T.
Publicado em 2014

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Por McIntyre, Kristi, O’Shaughnessy, Joyce, Schwartzberg, Lee, Glück, Stefan, Berrak, Erhan, Song, James X., Cox, David, Vahdat, Linda T.
Publicado no Breast Cancer Res Treat (2014)

Impact of race and tumor subtype on second malignancy risk in women with breast cancer

Por Diab, Nicholas, Clark, Gary, Langer, Lucy, Wang, Yunfei, Hamlington, Barbara, Brzeskiewicz, Laura, O’Shaughnessy, Joyce, Diab, Sami, Jabbour, Salma K.
Publicado no Springerplus (2016)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

Por Modi, Shanu, Saura, Cristina, Henderson, Charles, Lin, Nancy U., Mahtani, Reshma, Goddard, Jill, Rodenas, Eduardo, Hudis, Clifford, O’Shaughnessy, Joyce, Baselga, Jose
Publicado em 2013

Eribulin Monotherapy in Patients Aged 70 Years and Older With Metastatic Breast Cancer

Por Muss, Hyman, Cortes, Javier, Vahdat, Linda T., Cardoso, Fatima, Twelves, Chris, Wanders, Jantien, Dutcus, Corina E., Yang, Jay, Seegobin, Seth, O’Shaughnessy, Joyce
Publicado em 2014

Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort

Por Bonneterre, Jacques, Bosq, Jacques, Jamme, Philippe, Valent, Alexander, Gilles, Erard M, Zukiwski, Alexander A, Fuqua, Suzanne A W, Lange, Carol A, O'Shaughnessy, Joyce
Publicado no ESMO Open (2016)

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer...

Por Tripathy, Debu, Rugo, Hope S, Kaufman, Peter A, Swain, Sandra, O’Shaughnessy, Joyce, Jahanzeb, Mohammad, Mason, Ginny, Beattie, Mary, Yoo, Bongin, Lai, Catherine, Masaquel, Anthony, Hurvitz, Sara
Publicado em 2014

“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

Por Twelves, Christopher, Cortes, Javier, Kaufman, Peter A., Yelle, Louise, Awada, Ahmad, Binder, Terri A., Olivo, Martin, Song, James, O’Shaughnessy, Joyce A., Jove, Maria, Perez, Edith A.
Publicado no Breast Cancer Res (2015)

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

Por Cortés, Javier, Rugo, Hope S., Twelves, Chris, Awada, Ahmad, Perez, Edith A., Im, Seock-Ah, Zhao, Carol, Hoch, Ute, Tomkinson, Denise, Buchanan, James, Tagliaferri, Mary, Hannah, Alison, O’Shaughnessy, Joyce
Publicado no Springerplus (2016)

Tamoxifen Downregulates Ets-oncogene Family Members ETV4 and ETV5 in Benign Breast Tissue: Implications for Durable Risk Reduction

Por Euhus, David, Bu, Dawei, Xie, Xian-Jin, Sarode, Venetia, Ashfaq, Raheela, Hunt, Kelly, Xia, Weiya, O’Shaughnessy, Joyce, Grant, Michael, Arun, Banu, Dooley, William, Miller, Alexander, Flockhart, David, Lewis, Cheryl
Publicado em 2011

Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing

Por Leary, Rebecca J., Sausen, Mark, Kinde, Isaac, Papadopoulos, Nickolas, Carpten, John D., Craig, David, O’Shaughnessy, Joyce, Kinzler, Kenneth W., Parmigiani, Giovanni, Vogelstein, Bert, Diaz, Luis A., Velculescu, Victor E.
Publicado em 2012